Ani Pharmaceuticals SVP Ori Gutwerg sells $243,474 in common stock. By Investing.com
- Investing
Ramit Sethi- 3 minutes read
Ori Gutwerg, Senior Vice President of Generics at ANI Pharmaceuticals Inc. (), disposed of common stock valued at $243,474 on August 10, 2026.
The transaction involved the sale of 3,162 shares at a price of $77.00 per share. The stock currently trades at $74.53, near its 52-week low of $70.15, according to real-time data. Following the transaction, Mr. Gutwerg directly holds 75,534 shares of ANI Pharmaceuticals common stock, according to a Form 4 filing dated August 11, 2026. The company appears undervalued based on InvestingPro Fair Value analysis, with a market cap of $1.6 billion and P/E ratio of 17.24. For deeper insights, investors can access ANI’s comprehensive Pro Research Report, available for this and 1,400+ other US stocks on InvestingPro.
In other recent news, ANI Pharmaceuticals reported strong second-quarter 2026 results, with adjusted earnings of $2.21 per share, surpassing Wall Street’s estimate of $2.03. The company’s revenue reached a record $266 million, exceeding forecasts of $262.14 million. Despite these positive results, the company faced challenges with its Cortrophin product, which underperformed by $4 million in the second quarter. As a result, ANI Pharmaceuticals revised its full-year Cortrophin guidance down by $20 million to $25 million.
Guggenheim maintained a Buy rating on ANI Pharmaceuticals but lowered its price target from $124 to $119, acknowledging the company’s overall strong performance in Generics and Brand Royalties. Meanwhile, Canaccord Genuity also adjusted its price target for ANI Pharmaceuticals, reducing it slightly from $91 to $90, while maintaining a Hold rating. The firm noted the earnings miss and Cortrophin’s weaker-than-expected performance as reasons for the adjustment. These developments highlight the mixed reactions from analysts following ANI Pharmaceuticals’ recent earnings report.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
